Anti-VEGF Therapeutics Market Size

Anti-VEGF Therapeutics Market Future Prospects

The global anti-vascular endothelial growth factor therapeutics market revenue will stand at an estimated USD 24.4 billion in 2024, and it is expected to advance at a CAGR of 3.8% during 2025–2030, to reach USD 30.5 billion by 2030. The growth in the market is largely influenced by the FDA approvals for products in the pipeline along with research and development activities in this field.

Moreover, governments and private companies are funding research projects related to anti-VEGF treatment. For instance, Joslin Diabetes Center received funding from the National Institutes of Health, the U.S. Department of Health and Human Services, Regeneron and the DRCR Retina Network, to conduct research on early treatment of pre-existing diabetic eye disease with injections of anti-VEGF agent aflibercept. The results of the research depict that the progression of vision-threatening diabetic retinopathy (DR) problems slows down with the help of early treatment.

The growth can also be attributed to the rise in the prevalence of ophthalmic diseases like age-related macular degeneration (AMD), DR, macular edema, and retinal vein occlusion, as well as the growth in the aging population that increases the risk of developing several diseases. However, the regulatory restriction on elective surgeries during the COVID-19 pandemic impacted the market negatively, as patients did not have the required access to resources, and the disturbance in the supply chain in the industry.